{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T12:21:38Z","timestamp":1791030098189,"version":"4.1.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,9,26]],"date-time":"2010-09-26T00:00:00Z","timestamp":1285459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1007\/s00223-010-9420-x","type":"journal-article","created":{"date-parts":[[2010,9,25]],"date-time":"2010-09-25T06:35:20Z","timestamp":1285396520000},"page":"469-484","source":"Crossref","is-referenced-by-count":89,"title":["Impact of Treatments for Postmenopausal Osteoporosis (Bisphosphonates, Parathyroid Hormone, Strontium Ranelate, and Denosumab) on Bone Quality: A Systematic Review"],"prefix":"10.1007","volume":"87","author":[{"given":"S. J.","family":"Gallacher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,9,26]]},"reference":[{"key":"9420_CR1","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.bone.2003.12.022","volume":"34","author":"PD Delmas","year":"2004","unstructured":"Delmas PD, Seeman E (2004) Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with antiresorptive therapy. Bone 34:599\u2013604","journal-title":"Bone"},{"key":"9420_CR2","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archinte.164.10.1108","volume":"164","author":"ES Siris","year":"2004","unstructured":"Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE et al (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164:1108\u20131112","journal-title":"Arch Intern Med"},{"key":"9420_CR3","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1359\/jbmr.070413","volume":"22","author":"P Chen","year":"2007","unstructured":"Chen P, Miller PD, Recker R, Resch H, Rana A, Pavo I et al (2007) Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J Bone Miner Res 22:1173\u20131180","journal-title":"J Bone Miner Res"},{"key":"9420_CR4","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.bone.2007.04.198","volume":"41","author":"JJ Stepan","year":"2007","unstructured":"Stepan JJ, Burr DB, Pavo I, Sipos A, Michalska D, Li J et al (2007) Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone 41:378\u2013385","journal-title":"Bone"},{"key":"9420_CR5","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.injury.2007.08.036","volume":"39","author":"EB Kwek","year":"2008","unstructured":"Kwek EB, Goh SK, Koh JS, Png MA, Howe TS (2008) An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39:224\u2013231","journal-title":"Injury"},{"key":"9420_CR6","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","volume":"90","author":"CV Odvina","year":"2005","unstructured":"Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294\u20131301","journal-title":"J Clin Endocrinol Metab"},{"key":"9420_CR7","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1210\/jc.2007-2803","volume":"93","author":"M Visekruna","year":"2008","unstructured":"Visekruna M, Wilson D, McKiernan FE (2008) Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 93:2948\u20132952","journal-title":"J Clin Endocrinol Metab"},{"key":"9420_CR8","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3899\/jrheum.080759","volume":"36","author":"AA Khan","year":"2009","unstructured":"Khan AA, S\u00e1ndor GK, Dore E, Morrison AD, Alsahli M, Amin F, Canadian Taskforce on Osteonecrosis of the Jaw et al (2009) Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 36:478\u2013490","journal-title":"J Rheumatol"},{"key":"9420_CR9","doi-asserted-by":"crossref","first-page":"c246","DOI":"10.1136\/bmj.c246","volume":"340","author":"A Khan","year":"2010","unstructured":"Khan A (2010) Osteonecrosis of the jaw and bisphosphonates. BMJ 340:c246","journal-title":"BMJ"},{"key":"9420_CR10","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","volume":"22","author":"S Khosla","year":"2007","unstructured":"Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, American Society for Bone and Mineral Research et al (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479\u20131491","journal-title":"J Bone Miner Res"},{"key":"9420_CR11","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s00198-009-0994-y","volume":"20","author":"P Szulc","year":"2009","unstructured":"Szulc P, Seeman E (2009) Thinking inside and outside the envelopes of bone: dedicated to PDD. Osteoporos Int 20:1281\u20131288","journal-title":"Osteoporos Int"},{"key":"9420_CR12","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.bone.2006.09.008","volume":"40","author":"JE Compston","year":"2007","unstructured":"Compston JE (2007) Skeletal actions of intermittent parathyroid hormone: effects on bone remodeling and structure. Bone 40:1447\u20131452","journal-title":"Bone"},{"key":"9420_CR13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11926-003-0085-6","volume":"5","author":"AA Reszka","year":"2003","unstructured":"Reszka AA, Rodan GA (2003) Bisphosphonate mechanism of action. Curr Rheumatol Rep 5:65\u201374","journal-title":"Curr Rheumatol Rep"},{"key":"9420_CR14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","volume":"24","author":"JP Brown","year":"2009","unstructured":"Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH et al (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153\u2013161","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"9420_CR15","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/01.bor.0000229522.89546.7b","volume":"18","author":"PJ Marie","year":"2006","unstructured":"Marie PJ (2006) Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation. Curr Opin Rheumatol 18(Suppl 1):S11\u2013S15","journal-title":"Curr Opin Rheumatol"},{"key":"9420_CR16","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","volume":"350","author":"PJ Meunier","year":"2004","unstructured":"Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459\u2013468","journal-title":"N Engl J Med"},{"key":"9420_CR17","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY et al (2001) Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434\u20131441","journal-title":"N Engl J Med"},{"key":"9420_CR18","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1210\/jc.2003-1703","volume":"90","author":"H Dobnig","year":"2005","unstructured":"Dobnig H, Sipos A, Jiang Y, Fahrleitner-Pammer A, Ste-Marie LG, Gallagher JC et al (2005) Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 90:3970\u20133977","journal-title":"J Clin Endocrinol Metab"},{"key":"9420_CR19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11914-008-0005-9","volume":"6","author":"JP Bilezikian","year":"2008","unstructured":"Bilezikian JP (2008) Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. Curr Osteoporos Rep 6:24\u201330","journal-title":"Curr Osteoporos Rep"},{"key":"9420_CR20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S8756-3282(00)00316-1","volume":"27","author":"AB Hodsman","year":"2000","unstructured":"Hodsman AB, Kisiel M, Adachi JD, Fraher LJ, Watson PH (2000) Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2\u00a0years of cyclical hPTH(1\u201334) therapy in women with severe osteoporosis. Bone 27:311\u2013318","journal-title":"Bone"},{"key":"9420_CR21","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1359\/jbmr.060314","volume":"21","author":"YL Ma","year":"2006","unstructured":"Ma YL, Zeng Q, Donley DW, Ste-Marie LG, Gallagher JC, Dalsky GP et al (2006) Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res 21:855\u2013864","journal-title":"J Bone Miner Res"},{"key":"9420_CR22","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1359\/jbmr.070104","volume":"22","author":"R Lindsay","year":"2007","unstructured":"Lindsay R, Zhou H, Cosman F, Nieves J, Dempster DW, Hodsman AB (2007) Effects of a one-month treatment with PTH(1\u201334) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res 22:495\u2013502","journal-title":"J Bone Miner Res"},{"key":"9420_CR23","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1530\/EJE-07-0528","volume":"158","author":"AD Anastasilakis","year":"2008","unstructured":"Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Pavlidou V, Koukoulis G et al (2008) Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-kappaB ligand levels in women with established osteoporosis treated with teriparatide. Eur J Endocrinol 158:411\u2013415","journal-title":"Eur J Endocrinol"},{"key":"9420_CR24","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1359\/jbmr.2003.18.11.1932","volume":"18","author":"Y Jiang","year":"2003","unstructured":"Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF (2003) Recombinant human parathyroid hormone (1\u201334) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932\u20131941","journal-title":"J Bone Miner Res"},{"key":"9420_CR25","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1359\/jbmr.070603","volume":"22","author":"C Graeff","year":"2007","unstructured":"Graeff C, Timm W, Nickelsen TN, Farrerons J, Mar\u00edn F, Barker C, EUROFORS High Resolution Computed Tomography Substudy Group et al (2007) Monitoring teriparatide-associated changes in vertebral microstructure by high-resolution CT in vivo: results from the EUROFORS study. J Bone Miner Res 22:1426\u20131433","journal-title":"J Bone Miner Res"},{"key":"9420_CR26","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.bone.2008.09.019","volume":"44","author":"RR Recker","year":"2009","unstructured":"Recker RR, Bare SP, Smith SY, Varela A, Miller MA, Morris SA (2009) Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1\u201384. Bone 44:113\u2013119","journal-title":"Bone"},{"key":"9420_CR27","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1210\/er.2004-0006","volume":"26","author":"AB Hodsman","year":"2005","unstructured":"Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST et al (2005) Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26:688\u2013703","journal-title":"Endocr Rev"},{"key":"9420_CR28","first-page":"S97","volume":"28","author":"L Hyldstrup","year":"2002","unstructured":"Hyldstrup L, Jorgensen JT, Gaich G (2002) Assessment of effects of ly333334 [recombinant human parathyroid hormone (1\u201334)] on cortical bone using digital X-ray radiogrammetry. Bone 28:S97","journal-title":"Bone"},{"key":"9420_CR29","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1359\/jbmr.090820","volume":"25","author":"J Borggrefe","year":"2009","unstructured":"Borggrefe J, Graeff C, Nickelsen TN, Marin F, Gl\u00fcer CC (2009) Quantitative computed tomography assessment of the effects of 24\u00a0months of teriparatide treatment on 3-D femoral neck bone distribution, geometry and bone strength: results from the EUROFORS study. J Bone Miner Res 25:472\u2013481","journal-title":"J Bone Miner Res"},{"key":"9420_CR30","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1210\/jc.2004-2489","volume":"90","author":"EP Paschalis","year":"2005","unstructured":"Paschalis EP, Glass EV, Donley DW, Eriksen EF (2005) Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial. J Clin Endocrinol Metab 90:4644\u20134649","journal-title":"J Clin Endocrinol Metab"},{"key":"9420_CR31","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.bone.2005.03.003","volume":"36","author":"K Uusi-Rasi","year":"2005","unstructured":"Uusi-Rasi K, Semanick LM, Zanchetta JR, Bogado CE, Eriksen EF, Sato M et al (2005) Effects of teriparatide [rhPTH (1\u201334)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 36:948\u2013958","journal-title":"Bone"},{"key":"9420_CR32","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1359\/jbmr.2003.18.3.539","volume":"18","author":"JR Zanchetta","year":"2003","unstructured":"Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M et al (2003) Effects of teriparatide [recombinant human parathyroid hormone (1\u201334)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 18:539\u2013543","journal-title":"J Bone Miner Res"},{"key":"9420_CR33","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/147323000903700216","volume":"37","author":"Y Xiong","year":"2009","unstructured":"Xiong Y, Yang HJ, Feng J, Shi ZL, Wu LD (2009) Effects of alendronate on the proliferation and osteogenic differentiation of MG-63 cells. J Int Med Res 37:407\u2013416","journal-title":"J Int Med Res"},{"key":"9420_CR34","doi-asserted-by":"crossref","unstructured":"Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Welch V et al (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 1:CD001155. doi: 10.1002\/14651858.CD001155.pub2","DOI":"10.1002\/14651858.CD001155.pub2"},{"key":"9420_CR35","doi-asserted-by":"crossref","unstructured":"Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Welch V et al (2008) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 1: CD004523. doi: 10.1002\/14651858.CD004523.pub3","DOI":"10.1002\/14651858.CD004523.pub3"},{"key":"9420_CR36","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, for HORIZON Pivotal Fracture Trial et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"9420_CR37","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"CH Chesnut III","year":"2004","unstructured":"Chesnut CH III, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, for the Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America, Europe (BONE) et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241\u20131249","journal-title":"J Bone Miner Res"},{"key":"9420_CR38","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00198-008-0813-x","volume":"20","author":"E Seeman","year":"2009","unstructured":"Seeman E (2009) To stop or not to stop, that is the question. Osteoporos Int 20:187\u2013195","journal-title":"Osteoporos Int"},{"key":"9420_CR39","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1185\/030079904X20259","volume":"21","author":"R Recker","year":"2005","unstructured":"Recker R, Masarachia P, Santora A, Howard T, Chavassieux P, Arlot M et al (2005) Trabecular bone microarchitecture after alendronate treatment of osteoporotic women. Curr Med Res Opin 21:185\u2013194","journal-title":"Curr Med Res Opin"},{"key":"9420_CR40","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00223-002-2104-4","volume":"73","author":"TE Dufresne","year":"2003","unstructured":"Dufresne TE, Chmielewski PA, Manhart MD, Johnson TD, Borah B (2003) Risedronate preserves bone architecture in early postmenopausal women in 1\u00a0year as measured by three-dimensional microcomputed tomography. Calcif Tissue Int 73:423\u2013432","journal-title":"Calcif Tissue Int"},{"key":"9420_CR41","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1359\/jbmr.060701","volume":"21","author":"E Durchschlag","year":"2006","unstructured":"Durchschlag E, Paschalis EP, Zoehrer R, Roschger P, Fratzl P, Recker R et al (2006) Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate. J Bone Miner Res 21:1581\u20131590","journal-title":"J Bone Miner Res"},{"key":"9420_CR42","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.bone.2003.12.013","volume":"34","author":"B Borah","year":"2004","unstructured":"Borah B, Dufresne TE, Chmielewski PA, Johnson TD, Chines A, Manhart MD (2004) Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 34:736\u2013746","journal-title":"Bone"},{"key":"9420_CR43","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S8756-3282(01)00485-9","volume":"29","author":"P Roschger","year":"2001","unstructured":"Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzl P, Klaushofer K (2001) Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29:185\u2013191","journal-title":"Bone"},{"key":"9420_CR44","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1359\/jbmr.070906","volume":"23","author":"RR Recker","year":"2008","unstructured":"Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, Garc\u00eda-Hernandez PA et al (2008) Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 23:6\u201316","journal-title":"J Bone Miner Res"},{"key":"9420_CR45","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S8756-3282(00)00376-8","volume":"27","author":"GY Boivin","year":"2000","unstructured":"Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ (2000) Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687\u2013694","journal-title":"Bone"},{"key":"9420_CR46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2005.03.017","volume":"37","author":"B Borah","year":"2005","unstructured":"Borah B, Ritman EL, Dufresne TE, Jorgensen SM, Liu S, Sacha J et al (2005) The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover. Bone 37:1\u20139","journal-title":"Bone"},{"key":"9420_CR47","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bone.2006.01.161","volume":"39","author":"B Borah","year":"2006","unstructured":"Borah B, Dufresne TE, Ritman EL, Jorgensen SM, Liu S, Chmielewski PA et al (2006) Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone 39:345\u2013352","journal-title":"Bone"},{"key":"9420_CR48","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI119668","volume":"100","author":"PM Chavassieux","year":"1997","unstructured":"Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ (1997) Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475\u20131480","journal-title":"J Clin Invest"},{"key":"9420_CR49","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S8756-3282(02)00869-4","volume":"3","author":"EF Eriksen","year":"2002","unstructured":"Eriksen EF, Melsen F, Sod E, Barton I, Chines A (2002) Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 3:620\u2013625","journal-title":"Bone"},{"key":"9420_CR50","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1359\/jbmr.060401","volume":"21","author":"R Zoehrer","year":"2006","unstructured":"Zoehrer R, Roschger P, Paschalis EP, Hofstaetter JG, Durchschlag E, Fratzl P et al (2006) Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women. J Bone Miner Res 21:1106\u20131112","journal-title":"J Bone Miner Res"},{"key":"9420_CR51","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1359\/jbmr.090702","volume":"25","author":"P Roschger","year":"2010","unstructured":"Roschger P, Lombardi A, Misof BM, Maier G, Fratzl-Zelman N, Fratzl P et al (2010) Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the Fracture Intervention Trial Long-Term Extension (FLEX). J Bone Miner Res 25:48\u201355","journal-title":"J Bone Miner Res"},{"key":"9420_CR52","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00198-003-1530-0","volume":"15","author":"RR Recker","year":"2004","unstructured":"Recker RR, Weinstein RS, Chesnut CH III, Schimmer RC, Mahoney P, Hughes C et al (2004) Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int 15:231\u2013237","journal-title":"Osteoporos Int"},{"key":"9420_CR53","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2007.03.011","volume":"41","author":"M McClung","year":"2007","unstructured":"McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A et al (2007) Intravenous zoledronic acid 5\u00a0mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 41:122\u2013128","journal-title":"Bone"},{"key":"9420_CR54","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00198-008-0725-9","volume":"20","author":"AL Boskey","year":"2009","unstructured":"Boskey AL, Spevak L, Weinstein RS (2009) Spectroscopic markers of bone quality in alendronate-treated postmenopausal women. Osteoporos Int 20:793\u2013800","journal-title":"Osteoporos Int"},{"key":"9420_CR55","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s00776-008-1265-z","volume":"13","author":"K Iba","year":"2008","unstructured":"Iba K, Takada J, Hatakeyama N, Ozasa Y, Wada T, Yamashita T (2008) Changes in urinary NTX levels in patients with primary osteoporosis undergoing long-term bisphosphonate treatment. J Orthop Sci 13:438\u2013441","journal-title":"J Orthop Sci"},{"key":"9420_CR56","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1359\/jbmr.070609","volume":"22","author":"RD Chapurlat","year":"2007","unstructured":"Chapurlat RD, Arlot M, Burt-Pichat B, Chavassieux P, Roux JP, Portero-Muzy N et al (2007) Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res 22:1502\u20131509","journal-title":"J Bone Miner Res"},{"key":"9420_CR57","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00198-009-0899-9","volume":"20","author":"RD Chapurlat","year":"2009","unstructured":"Chapurlat RD, Delmas PD (2009) Bone microdamage: a clinical perspective. Osteoporos Int 20:1299\u20131308","journal-title":"Osteoporos Int"},{"key":"9420_CR58","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa1001086","volume":"362","author":"DM Black","year":"2010","unstructured":"Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, the Fracture Intervention Trial and HORIZON Pivotal Fracture Trial Steering Committees et al (2010) Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 362:1761\u20131771","journal-title":"N Engl J Med"},{"key":"9420_CR59","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1056\/NEJMe1003064","volume":"362","author":"E Shane","year":"2010","unstructured":"Shane E (2010) Evolving data about subtrochanteric fractures and bisphosphonates. N Engl J Med 362:1825\u20131827","journal-title":"N Engl J Med"},{"key":"9420_CR60","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1359\/JBMR.050309","volume":"20","author":"M Arlot","year":"2005","unstructured":"Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, Correa-Rotter R et al (2005) Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 20:1244\u20131253","journal-title":"J Bone Miner Res"},{"key":"9420_CR61","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1359\/jbmr.061011","volume":"22","author":"TM Keaveny","year":"2007","unstructured":"Keaveny TM, Donley DW, Hoffmann PF, Mitlak BH, Glass EV, San Martin JA (2007) Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res 22:149\u2013157","journal-title":"J Bone Miner Res"},{"key":"9420_CR62","doi-asserted-by":"crossref","unstructured":"Fonseca JE (2008) Rebalancing bone turnover in favour of formation with strontium ranelate: implications for bone strength. Rheumatology (Oxford) 47(Suppl 4):iv17\u2013iv19","DOI":"10.1093\/rheumatology\/ken165"},{"key":"9420_CR63","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1365-2265.2008.03342.x","volume":"70","author":"AD Anastasilakis","year":"2009","unstructured":"Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Ballaouri I, Efstathiadou Z et al (2009) No difference between strontium ranelate (SR) and calcium\/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial. Clin Endocrinol (Oxf) 70:522\u2013526","journal-title":"Clin Endocrinol (Oxf)"},{"key":"9420_CR64","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1055\/s-0029-1192035","volume":"41","author":"AD Anastasilakis","year":"2009","unstructured":"Anastasilakis AD, Polyzos SA, Avramidis A, Papatheodorou A, Terpos E (2009) Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide. Horm Metab Res 41:559\u2013562","journal-title":"Horm Metab Res"},{"key":"9420_CR65","doi-asserted-by":"crossref","unstructured":"O\u2019Donnell S, Cranney A, Wells GA, Adachi J, Reginster JY (2006) Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev 4:CD005326. doi: 10.1002\/14651858.CD005326.pub3","DOI":"10.1002\/14651858.CD005326.pub3"},{"key":"9420_CR66","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1210\/jc.2004-1774","volume":"90","author":"JY Reginster","year":"2005","unstructured":"Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C et al (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816\u20132822","journal-title":"J Clin Endocrinol Metab"},{"key":"9420_CR67","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1359\/jbmr.071012","volume":"23","author":"ME Arlot","year":"2008","unstructured":"Arlot ME, Jiang Y, Genant HK, Zhao J, Burt-Pichat B, Roux JP et al (2008) Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res 23:215\u2013222","journal-title":"J Bone Miner Res"},{"key":"9420_CR68","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1359\/jbmr.090702","volume":"25","author":"P Roschger","year":"2010","unstructured":"Roschger P, Manjubala I, Zoeger N, Meirer F, Simon R et al (2010) Bone material quality in transiliac bone biopsies of postmenopausal osteoporotic women after 3\u00a0years of strontium ranelate treatment. J Bone Miner Res 25:891\u2013900","journal-title":"J Bone Miner Res"},{"key":"9420_CR69","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00198-009-1005-z","volume":"21","author":"G Boivin","year":"2010","unstructured":"Boivin G, Farlay D, Khebbab MT, Jaurand X, Delmas PD, Meunier PJ (2010) In osteoporotic women treated with strontium ranelate, strontium is located in bone formed during treatment with a maintained degree of mineralization. Osteoporos Int 21:667\u2013677","journal-title":"Osteoporos Int"},{"key":"9420_CR70","first-page":"830","volume":"8","author":"LB Tank\u00f3","year":"2007","unstructured":"Tank\u00f3 LB (2007) Effect of RANKL-specific denosumab on osteoclast number and function: a potential friend or foe? Curr Opin Investig Drugs 8:830\u2013835","journal-title":"Curr Opin Investig Drugs"},{"key":"9420_CR71","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, FREEDOM Trial et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"9420_CR72","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jocd.2008.04.001","volume":"11","author":"TJ Beck","year":"2008","unstructured":"Beck TJ, Lewiecki EM, Miller PD, Felsenberg D, Liu Y, Ding B (2008) Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. J Clin Densitom 11:351\u2013359","journal-title":"J Clin Densitom"},{"key":"9420_CR73","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","volume":"25","author":"DL Kendler","year":"2009","unstructured":"Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S et al (2009) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 25:72\u201381","journal-title":"J Bone Miner Res"},{"key":"9420_CR74","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.bone.2006.02.003","volume":"39","author":"PD Delmas","year":"2006","unstructured":"Delmas PD, Licata AA, Reginster JY, Crans GG, Chen P, Misurski DA et al (2006) Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone 39:237\u2013243","journal-title":"Bone"},{"key":"9420_CR75","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1210\/jc.2007-0711","volume":"93","author":"S Boonen","year":"2008","unstructured":"Boonen S, Marin F, Obermayer-Pietsch B, Simoes ME, Barker C, Glass EV et al (2008) Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 93:852\u2013860","journal-title":"J Clin Endocrinol Metab"},{"key":"9420_CR76","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1210\/jc.2008-0353","volume":"93","author":"PD Miller","year":"2008","unstructured":"Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J et al (2008) Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 93:3785\u20133793","journal-title":"J Clin Endocrinol Metab"},{"key":"9420_CR77","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00223-007-9066-5","volume":"81","author":"ET Middleton","year":"2007","unstructured":"Middleton ET, Steel SA, Doherty SM (2007) The effect of prior bisphosphonate exposure on the treatment response to teriparatide in clinical practice. Calcif Tissue Int 81:335\u2013340","journal-title":"Calcif Tissue Int"},{"key":"9420_CR78","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1359\/jbmr.080506","volume":"10","author":"BM Obermayer-Pietsch","year":"2008","unstructured":"Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S, EUROFORS Investigators et al (2008) Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 10:1591\u20131600","journal-title":"J Bone Miner Res"},{"key":"9420_CR79","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/03008200802412462","volume":"50","author":"B Jobke","year":"2009","unstructured":"Jobke B, Pfeifer M, Minne HW (2009) Teriparatide following bisphosphonates: initial and long-term effects on microarchitecture and bone remodeling at the human iliac crest. Connect Tissue Res 50:46\u201354","journal-title":"Connect Tissue Res"},{"key":"9420_CR80","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1359\/jbmr.090527","volume":"24","author":"H Dobnig","year":"2009","unstructured":"Dobnig H, Stepan JJ, Burr DB, Li J, Michalska D, Sipos A et al (2009) Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate. J Bone Miner Res 24:1998\u20132006","journal-title":"J Bone Miner Res"},{"key":"9420_CR81","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1210\/jc.2008-2630","volume":"94","author":"BZ Leder","year":"2009","unstructured":"Leder BZ, Neer RM, Wyland JJ, Lee HW, Burnett-Bowie SA, Finkelstein JS (2009) Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab 94:2915\u20132921","journal-title":"J Clin Endocrinol Metab"},{"key":"9420_CR82","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1210\/jc.2009-0154","volume":"94","author":"JS Finkelstein","year":"2009","unstructured":"Finkelstein JS, Wyland JJ, Leder BZ, Burnett-Bowie SM, Lee H, J\u00fcppner H et al (2009) Effects of teriparatide retreatment in osteoporotic men and women. J Clin Endocrinol Metab 94:2495\u20132501","journal-title":"J Clin Endocrinol Metab"},{"key":"9420_CR83","first-page":"2129","volume":"85","author":"RS Rittmaster","year":"2000","unstructured":"Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL et al (2000) Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85:2129\u20132134","journal-title":"J Clin Endocrinol Metab"},{"key":"9420_CR84","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","volume":"349","author":"DM Black","year":"2003","unstructured":"Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, PaTH Study Investigators et al (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207\u20131215","journal-title":"N Engl J Med"},{"key":"9420_CR85","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","volume":"353","author":"DM Black","year":"2005","unstructured":"Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T et al (2005) One year of alendronate after one year of parathyroid hormone (1\u201384) for osteoporosis. N Engl J Med 353:555\u2013565","journal-title":"N Engl J Med"},{"key":"9420_CR86","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1359\/jbmr.080805","volume":"23","author":"TM Keaveny","year":"2008","unstructured":"Keaveny TM, Hoffmann PF, Singh M, Palermo L, Bilezikian JP, Greenspan SL et al (2008) Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res 23:1974\u20131982","journal-title":"J Bone Miner Res"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-010-9420-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00223-010-9420-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-010-9420-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T11:37:59Z","timestamp":1558697879000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-010-9420-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,26]]},"references-count":86,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["9420"],"URL":"https:\/\/doi.org\/10.1007\/s00223-010-9420-x","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,26]]}}}